DePuy Synthes Acquires Orthotaxy to Develop Robotic-Assisted Surgery Platform

Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies, including a differentiated robotic-assisted surgery solution. This proprietary technology is currently in early-stage development for total and partial knee replacement, and the Johnson & Johnson Medical Devices Companies plan to broaden its application for a range of orthopedic surgery procedures.
 
The goal is to build a next-generation robotic-assisted orthopedic surgery solution that is cost-effective, time-efficient, and user-friendly in a variety of care settings. Orthotaxy’s technology will be a critical part of a complete orthopedic solution that uses enabling technologies to personalize procedures, optimize surgery and bring value to customers and patients. Founded by Stéphane Lavallée, a robotics entrepreneur, Orthotaxy designs and develops computer-assisted platforms.
 
“Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopedics platform, delivering value to patients, physicians and healthcare providers across the episode of care,” said Ciro Rӧmer, Company Group Chairman of DePuy Synthes, the orthopedics business of Johnson & Johnson. “The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction.”
 
This acquisition underscores the companies’ commitment in building an innovative and comprehensive digital surgery platform that brings value to customers and improves the standard of care for as many patients as possible. Moving forward, Johnson & Johnson Medical Devices Companies will focus on digital technology solutions that expand beyond providing best-in-class products to transformative solutions across the full continuum of care.
 
Financial terms of the transaction will not be disclosed.